Literature DB >> 27820605

Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.

Jiwon Lee1, Daniel R Boutz2, Veronika Chromikova3, M Gordon Joyce4, Christopher Vollmers5, Kwanyee Leung4, Andrew P Horton2, Brandon J DeKosky1, Chang-Han Lee1, Jason J Lavinder1, Ellen M Murrin1, Constantine Chrysostomou1, Kam Hon Hoi6, Yaroslav Tsybovsky7, Paul V Thomas4, Aliaksandr Druz4, Baoshan Zhang4, Yi Zhang4, Lingshu Wang4, Wing-Pui Kong4, Daechan Park1, Lyubov I Popova8, Cornelia L Dekker9, Mark M Davis10,11, Chalise E Carter12, Ted M Ross12, Andrew D Ellington2,13, Patrick C Wilson8, Edward M Marcotte2,13, John R Mascola4, Gregory C Ippolito13, Florian Krammer3, Stephen R Quake5,10,14, Peter D Kwong4, George Georgiou1,2,6,13.   

Abstract

Molecular understanding of serological immunity to influenza has been confounded by the complexity of the polyclonal antibody response in humans. Here we used high-resolution proteomics analysis of immunoglobulin (referred to as Ig-seq) coupled with high-throughput sequencing of transcripts encoding B cell receptors (BCR-seq) to quantitatively determine the antibody repertoire at the individual clonotype level in the sera of young adults before and after vaccination with trivalent seasonal influenza vaccine. The serum repertoire comprised between 40 and 147 clonotypes that were specific to each of the three monovalent components of the trivalent influenza vaccine, with boosted pre-existing clonotypes accounting for ∼60% of the response. An unexpectedly high fraction of serum antibodies recognized both the H1 and H3 monovalent vaccines. Recombinant versions of these H1 + H3 cross-reactive antibodies showed broad binding to hemagglutinins (HAs) from previously circulating virus strains; several of these antibodies, which were prevalent in the serum of multiple donors, recognized the same conserved epitope in the HA head domain. Although the HA-head-specific H1 + H3 antibodies did not show neutralization activity in vitro, they protected mice against infection with the H1N1 and H3N2 virus strains when administered before or after challenge. Collectively, our data reveal unanticipated insights regarding the serological response to influenza vaccination and raise questions about the added benefits of using a quadrivalent vaccine instead of a trivalent vaccine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27820605      PMCID: PMC5301914          DOI: 10.1038/nm.4224

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  58 in total

1.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

Review 2.  Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire.

Authors:  Yariv Wine; Andrew P Horton; Gregory C Ippolito; George Georgiou
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

3.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

4.  Immunity to influenza as related to antibody levels.

Authors:  J A Morris; J A Kasel; M Saglam; V Knight; F A Loda
Journal:  N Engl J Med       Date:  1966-03-10       Impact factor: 91.245

5.  Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses.

Authors:  Yoshitaka Iba; Yoshifumi Fujii; Nobuko Ohshima; Tomomi Sumida; Ritsuko Kubota-Koketsu; Mariko Ikeda; Motoaki Wakiyama; Mikako Shirouzu; Jun Okada; Yoshinobu Okuno; Yoshikazu Kurosawa; Shigeyuki Yokoyama
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

6.  Variation in the human immune system is largely driven by non-heritable influences.

Authors:  Petter Brodin; Vladimir Jojic; Tianxiang Gao; Sanchita Bhattacharya; Cesar J Lopez Angel; David Furman; Shai Shen-Orr; Cornelia L Dekker; Gary E Swan; Atul J Butte; Holden T Maecker; Mark M Davis
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

7.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

8.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

9.  Viral receptor-binding site antibodies with diverse germline origins.

Authors:  Aaron G Schmidt; Matthew D Therkelsen; Shaun Stewart; Thomas B Kepler; Hua-Xin Liao; M Anthony Moody; Barton F Haynes; Stephen C Harrison
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

10.  Antibody landscapes after influenza virus infection or vaccination.

Authors:  J M Fonville; S H Wilks; S L James; A Fox; M Ventresca; M Aban; L Xue; T C Jones; N M H Le; Q T Pham; N D Tran; Y Wong; A Mosterin; L C Katzelnick; D Labonte; T T Le; G van der Net; E Skepner; C A Russell; T D Kaplan; G F Rimmelzwaan; N Masurel; J C de Jong; A Palache; W E P Beyer; Q M Le; T H Nguyen; H F L Wertheim; A C Hurt; A D M E Osterhaus; I G Barr; R A M Fouchier; P W Horby; D J Smith
Journal:  Science       Date:  2014-11-21       Impact factor: 47.728

View more
  128 in total

Review 1.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

Review 2.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

3.  Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.

Authors:  Florian Krammer; Peter Palese
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

4.  Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain.

Authors:  Donald D Raymond; Shaun M Stewart; Jiwon Lee; Jack Ferdman; Goran Bajic; Khoi T Do; Michael J Ernandes; Pirada Suphaphiphat; Ethan C Settembre; Philip R Dormitzer; Giuseppe Del Giudice; Oretta Finco; Tae Hyun Kang; Gregory C Ippolito; George Georgiou; Thomas B Kepler; Barton F Haynes; M Anthony Moody; Hua-Xin Liao; Aaron G Schmidt; Stephen C Harrison
Journal:  Nat Med       Date:  2016-11-07       Impact factor: 53.440

Review 5.  Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach.

Authors:  Christopher M Tipton; Jennifer R Hom; Christopher F Fucile; Alexander F Rosenberg; Inaki Sanz
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

6.  Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism.

Authors:  Akiko Watanabe; Kevin R McCarthy; Masayuki Kuraoka; Aaron G Schmidt; Yu Adachi; Taishi Onodera; Keisuke Tonouchi; Timothy M Caradonna; Goran Bajic; Shengli Song; Charles E McGee; Gregory D Sempowski; Feng Feng; Patricia Urick; Thomas B Kepler; Yoshimasa Takahashi; Stephen C Harrison; Garnett Kelsoe
Journal:  Cell       Date:  2019-05-16       Impact factor: 41.582

7.  Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States.

Authors:  Brendan Flannery; Catherine Smith; Rebecca J Garten; Min Z Levine; Jessie R Chung; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard Zimmerman; Mary Patricia Nowalk; Marie R Griffin; H Keipp Talbot; John J Treanor; David E Wentworth; Alicia M Fry
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

8.  Mapping a Conformational Epitope of Hemagglutinin A Using Native Mass Spectrometry and Ultraviolet Photodissociation.

Authors:  M Rachel Mehaffey; Jiwon Lee; Jiwon Jung; Michael B Lanzillotti; Edwin E Escobar; Keith R Morgenstern; George Georgiou; Jennifer S Brodbelt
Journal:  Anal Chem       Date:  2020-08-12       Impact factor: 6.986

9.  Anti-influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface.

Authors:  Jinhui Dong; Iuliia Gilchuk; Sheng Li; Ryan Irving; Matthew T Goff; Hannah L Turner; Andrew B Ward; Robert H Carnahan; James E Crowe
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

10.  Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface.

Authors:  Seth J Zost; Jinhui Dong; Iuliia M Gilchuk; Pavlo Gilchuk; Natalie J Thornburg; Sandhya Bangaru; Nurgun Kose; Jessica A Finn; Robin Bombardi; Cinque Soto; Elaine C Chen; Rachel S Nargi; Rachel E Sutton; Ryan P Irving; Naveenchandra Suryadevara; Jonna B Westover; Robert H Carnahan; Hannah L Turner; Sheng Li; Andrew B Ward; James E Crowe
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.